NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

重度抑鬱症(MDD) - 市場洞察,流行病學,市場預測 ∼2027年

Major Depressive Disorder - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 602082
出版日期 按訂單生產 內容資訊 英文 150 Pages
商品交期: 10個工作天內
價格
重度抑鬱症(MDD) - 市場洞察,流行病學,市場預測 ∼2027年 Major Depressive Disorder - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 150 Pages
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的重度抑鬱症(MDD)市場相關調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,未滿足需求,各治療藥物的市場規模的變化的預測,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 報告概要

第2章 重度抑鬱症(MDD)市場概要

  • 市場規模(成果值)
  • 市場規模(預測值)

第3章 疾病的背景和概要:重度抑鬱症(MDD)

  • 簡介
  • 原因
  • 病理生理學
  • 症狀
  • 風險因素
  • 診斷

第4章 流行病學和患者人口

  • 主要7個國家的患病數
  • 主要7個國家的患病數:性別(實數、預測值)
  • 主要7個國家的診斷數和可治療的病例數(實數、預測值)

第5章 疾病的流行病學:各國

  • 美國
    • 患病數
    • 患病數:性別(實數、預測值)
    • 診斷數和可治療的病例數(實數、預測值)
  • 歐盟5國
    • 德國
      • 患病數
      • 患病數:性別(實數、預測值)
      • 診斷數和可治療的病例數(實數、預測值)
    • 法國
      • 患病數
      • 患病數:性別(實數、預測值)
      • 診斷數和可治療的病例數(實數、預測值)
    • 義大利
      • 患病數
      • 患病數:性別(實數、預測值)
      • 診斷數和可治療的病例數(實數、預測值)
    • 西班牙
      • 患病數
      • 患病數:性別(實數、預測值)
      • 診斷數和可治療的病例數(實數、預測值)
    • 英國
      • 患病數
      • 患病數:性別(實數、預測值)
      • 診斷數和可治療的病例數(實數、預測值)
  • 日本
    • 患病數
    • 患病數:性別(實數、預測值)
    • 診斷數和可治療的病例數(實數、預測值)

第6章 治療行為

  • 治療流程
  • 治療指南

第7章 已上市醫藥品

  • Aripiprazole:BristolMyers Squibb
    • 產品說明
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介
  • Aplenzin:Valeant Pharmaceuticals

第8章 新藥

  • Key Cross Competition
  • Travivo:Fabre-Kramer Pharmaceuticals
    • 法規的里程碑
    • 臨床開發
    • 產品簡介
    • 臨床實驗平台活動
  • SAGE-217:Sage Therapeutics

第9章 重度抑鬱症(MDD)市場規模

  • 主要的觀察
  • 主要7個國家的市場分析
    • 市場概要
    • 市場規模的變化與預測:各地區

第10章 分析:各國主要7個國家

  • 美國
    • 市場規模
    • 市場規模:各治療藥物
  • 德國
    • 市場規模
    • 市場規模:各治療藥物
  • 法國
    • 市場規模
    • 市場規模:各治療藥物
  • 英國
    • 市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 市場規模
    • 市場規模:各治療藥物
  • 日本
    • 市場規模
    • 市場規模:各治療藥物

第11章 市場成長要素

第12章 市場障礙

第13章 調查方法

  • 參考資料的清單

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

目錄
Product Code: DIMI0314

DelveInsight's "Major Depressive Disorder - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Major Depressive Disorder market report provides current treatment practices, emerging drugs, Major Depressive Disorder market share of the individual therapies, current and forecasted Major Depressive Disorder market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Major Depressive Disorder treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Major Depressive Disorder Disease Understanding and Treatment Algorithm

The DelveInsight Major Depressive Disorder market report gives a thorough understanding of the Major Depressive Disorder by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Major Depressive Disorder.

Treatment

It covers the details of conventional and current medical therapies available in the Major Depressive Disorder market for the treatment of the condition. It also provides Major Depressive Disorder treatment algorithms and guidelines in the United States, Europe, and Japan.

Major Depressive Disorder Epidemiology

The Major Depressive Disorder epidemiology division provide insights about historical and current Major Depressive Disorder patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Major Depressive Disorder epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Major Depressive Disorder Epidemiology

The epidemiology segment also provides the Major Depressive Disorder epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Major Depressive Disorder Drug Chapters

Drug chapter segment of the Major Depressive Disorder report encloses the detailed analysis of Major Depressive Disorder marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Major Depressive Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Major Depressive Disorder treatment.

Major Depressive Disorder Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Major Depressive Disorder treatment.

Major Depressive Disorder Market Outlook

The Major Depressive Disorder market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Major Depressive Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Major Depressive Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Major Depressive Disorder market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Major Depressive Disorder market in 7MM.

The United States Market Outlook

This section provides the total Major Depressive Disorder market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Major Depressive Disorder market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Major Depressive Disorder market size and market size by therapies in Japan is also mentioned.

Major Depressive Disorder Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Major Depressive Disorder market or expected to get launched in the market during the study period 2017-2030. The analysis covers Major Depressive Disorder market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Major Depressive Disorder Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Major Depressive Disorder key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Major Depressive Disorder emerging therapies.

Reimbursement Scenario in Major Depressive Disorder

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Major Depressive Disorder domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Major Depressive Disorder market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Major Depressive Disorder Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Major Depressive Disorder, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Major Depressive Disorder epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Major Depressive Disorder are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Major Depressive Disorder market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Major Depressive Disorder market

Report Highlights

  • In the coming years, Major Depressive Disorder market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Major Depressive Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Major Depressive Disorder. Launch of emerging therapies will significantly impact the Major Depressive Disorder market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Major Depressive Disorder
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Major Depressive Disorder Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Major Depressive Disorder Pipeline Analysis
  • Major Depressive Disorder Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Major Depressive Disorder Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Major Depressive Disorder Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Major Depressive Disorder Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Major Depressive Disorder market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Major Depressive Disorder total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Major Depressive Disorder market size during the forecast period (2017-2030)?
  • At what CAGR, the Major Depressive Disorder market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Major Depressive Disorder market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Major Depressive Disorder market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Major Depressive Disorder?
  • What is the historical Major Depressive Disorder patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Major Depressive Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Major Depressive Disorder?
  • Out of all 7MM countries, which country would have the highest prevalent population of Major Depressive Disorder during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Major Depressive Disorder treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Major Depressive Disorder in the USA, Europe, and Japan?
  • What are the Major Depressive Disorder marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Major Depressive Disorder?
  • How many therapies are developed by each company for Major Depressive Disorder treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Major Depressive Disorder treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Major Depressive Disorder therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Major Depressive Disorder and their status?
  • What are the key designations that have been granted for the emerging therapies for Major Depressive Disorder?
  • What are the global historical and forecasted market of Major Depressive Disorder?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Major Depressive Disorder market
  • To understand the future market competition in the Major Depressive Disorder market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Major Depressive Disorder in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Major Depressive Disorder market
  • To understand the future market competition in the Major Depressive Disorder market

Table of Contents

1. Key Insights

2. Executive Summary of Major Depressive Disorder

3. Competitive Intelligence Analysis for Major Depressive Disorder

4. Major Depressive Disorder: Market Overview at a Glance

  • 4.1. Major Depressive Disorder Total Market Share (%) Distribution in 2017
  • 4.2. Major Depressive Disorder Total Market Share (%) Distribution in 2030

5. Major Depressive Disorder: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Major Depressive Disorder Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Major Depressive Disorder Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Major Depressive Disorder Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Major Depressive Disorder Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Major Depressive Disorder Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Major Depressive Disorder Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Major Depressive Disorder Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Major Depressive Disorder Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Major Depressive Disorder Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Major Depressive Disorder Treatment and Management
  • 8.2. Major Depressive Disorder Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Major Depressive Disorder Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Major Depressive Disorder: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Major Depressive Disorder Market Size in 7MM
  • 13.3. Major Depressive Disorder Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Major Depressive Disorder Total Market Size in the United States
    • 15.1.2. Major Depressive Disorder Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Major Depressive Disorder Total Market Size in Germany
    • 15.3.2. Major Depressive Disorder Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Major Depressive Disorder Total Market Size in France
    • 15.4.2. Major Depressive Disorder Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Major Depressive Disorder Total Market Size in Italy
    • 15.5.2. Major Depressive Disorder Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Major Depressive Disorder Total Market Size in Spain
    • 15.6.2. Major Depressive Disorder Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Major Depressive Disorder Total Market Size in the United Kingdom
    • 15.7.2. Major Depressive Disorder Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Major Depressive Disorder Total Market Size in Japan
    • 15.8.3. Major Depressive Disorder Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Major Depressive Disorder

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Major Depressive Disorder Epidemiology (2017-2030)
  • Table 2 : 7MM Major Depressive Disorder Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Major Depressive Disorder Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Major Depressive Disorder Epidemiology in Germany (2017-2030)
  • Table 6 : Major Depressive Disorder Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Major Depressive Disorder Epidemiology in France (2017-2030)
  • Table 8 : Major Depressive Disorder Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Major Depressive Disorder Epidemiology in Italy (2017-2030)
  • Table 10 : Major Depressive Disorder Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Major Depressive Disorder Epidemiology in Spain (2017-2030)
  • Table 12 : Major Depressive Disorder Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Major Depressive Disorder Epidemiology in the UK (2017-2030)
  • Table 14 : Major Depressive Disorder Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Major Depressive Disorder Epidemiology in Japan (2017-2030)
  • Table 16 : Major Depressive Disorder Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Major Depressive Disorder Epidemiology (2017-2030)
  • Figure 2 : 7MM Major Depressive Disorder Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Major Depressive Disorder Epidemiology in the United States (2017-2030)
  • Figure 4 : Major Depressive Disorder Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Major Depressive Disorder Epidemiology in Germany (2017-2030)
  • Figure 6 : Major Depressive Disorder Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Major Depressive Disorder Epidemiology in France (2017-2030)
  • Figure 8 : Major Depressive Disorder Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Major Depressive Disorder Epidemiology in Italy (2017-2030)
  • Figure 10 : Major Depressive Disorder Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Major Depressive Disorder Epidemiology in Spain (2017-2030)
  • Figure 12 : Major Depressive Disorder Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Major Depressive Disorder Epidemiology in the UK (2017-2030)
  • Figure 14 : Major Depressive Disorder Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Major Depressive Disorder Epidemiology in Japan (2017-2030)
  • Figure 16 : Major Depressive Disorder Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)